Jim Simons Graybug Vision, Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.46 - $1.05 $20,466 - $46,716	-44,492 Reduced 22.19%	156,000 $78,000
Q3 2022 Nov 14, 2022	BUY	$0.93 - $1.18 $138,004 - $175,102	148,392 Added 284.82%	200,492 $189,000
Q2 2022 Aug 12, 2022	BUY	$0.76 - $1.25 $12,736 - $20,948	16,759 Added 47.42%	52,100 $57,000
Q1 2022 May 13, 2022	BUY	$1.13 - $1.93 $27,505 - $46,978	24,341 Added 221.28%	35,341 $43,000
Q4 2021 Feb 11, 2022	BUY	$1.74 - $3.6 $19,140 - $39,600	11,000 New	11,000 $20,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.